D
Bausch Health Companies Inc.
BHC
$7.15
-$0.06-0.83%
D
Sell
1/29/2025Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 1/29/2025 due to an increase in the volatility index and valuation index.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 1/29/2025 due to an increase in the volatility index and valuation index.
E
Sell
1/10/2025Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 1/10/2025 due to a decline in the volatility index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 1/10/2025 due to a decline in the volatility index.
D
Sell
11/5/2024Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 11/5/2024 due to an increase in the total return index and volatility index.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 11/5/2024 due to an increase in the total return index and volatility index.
E
Sell
10/15/2024Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 10/15/2024 due to a decline in the volatility index and valuation index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 10/15/2024 due to a decline in the volatility index and valuation index.
D
Sell
9/11/2024Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 9/11/2024 due to an increase in the volatility index and total return index.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 9/11/2024 due to an increase in the volatility index and total return index.
E
Sell
8/23/2024Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 8/23/2024 due to a decline in the volatility index and total return index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 8/23/2024 due to a decline in the volatility index and total return index.
D
Sell
8/6/2024Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 8/6/2024 due to an increase in the volatility index, valuation index and solvency index.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 8/6/2024 due to an increase in the volatility index, valuation index and solvency index.
E
Sell
7/25/2024Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 7/25/2024 due to a decline in the total return index and volatility index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 7/25/2024 due to a decline in the total return index and volatility index.
D
Sell
7/9/2024Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 7/9/2024 due to an increase in the volatility index.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 7/9/2024 due to an increase in the volatility index.
E
Sell
6/20/2024Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 6/20/2024 due to a decline in the volatility index and total return index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 6/20/2024 due to a decline in the volatility index and total return index.
D
Sell
5/31/2024Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 5/31/2024 due to an increase in the volatility index and valuation index.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 5/31/2024 due to an increase in the volatility index and valuation index.
E
Sell
5/14/2024Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 5/14/2024 due to a decline in the volatility index and valuation index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 5/14/2024 due to a decline in the volatility index and valuation index.
D
Sell
2/26/2024Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 2/26/2024 due to a substantial decline in the efficiency index and volatility index.
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 2/26/2024 due to a substantial decline in the efficiency index and volatility index.
D
Sell
8/7/2023Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D from D- on 8/7/2023 due to a substantial increase in the efficiency index, total return index and solvency index. Net income increased 112.94% from -$201M to $26M, debt to equity declined from -25.82 to -31, and the quick ratio increased from 0.56 to 0.59.
Bausch Health Companies Inc. (BHC) was upgraded to D from D- on 8/7/2023 due to a substantial increase in the efficiency index, total return index and solvency index. Net income increased 112.94% from -$201M to $26M, debt to equity declined from -25.82 to -31, and the quick ratio increased from 0.56 to 0.59.
D
Sell
7/31/2023Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 7/31/2023 due to an increase in the volatility index and total return index.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 7/31/2023 due to an increase in the volatility index and total return index.
E
Sell
7/14/2023Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 7/14/2023 due to a decline in the volatility index, total return index and valuation index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 7/14/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
6/23/2023Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 6/23/2023 due to an increase in the volatility index and valuation index.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 6/23/2023 due to an increase in the volatility index and valuation index.
E
Sell
6/7/2023Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index, total return index and valuation index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/10/2023Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 5/10/2023 due to a large increase in the growth index, volatility index and valuation index. Earnings per share increased from -$1.13 to -$0.5533.
Bausch Health Companies Inc. (BHC) was upgraded to D- from E+ on 5/10/2023 due to a large increase in the growth index, volatility index and valuation index. Earnings per share increased from -$1.13 to -$0.5533.
E
Sell
5/9/2023Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index and total return index.
Bausch Health Companies Inc. (BHC) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 03/14/2023.
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 03/14/2023.
D
Sell
2/27/2023Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 2/27/2023 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 202.76% from $399M to -$410M, earnings per share declined from $1.1 to -$1.13, and total capital declined 1.79% from $21.65B to $21.26B.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 2/27/2023 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 202.76% from $399M to -$410M, earnings per share declined from $1.1 to -$1.13, and total capital declined 1.79% from $21.65B to $21.26B.
D
Sell
2/21/2023Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 2/21/2023 due to an increase in the volatility index and total return index.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 2/21/2023 due to an increase in the volatility index and total return index.
D
Sell
2/3/2023Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 2/3/2023 due to a decline in the valuation index and volatility index.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 2/3/2023 due to a decline in the valuation index and volatility index.
D
Sell
1/17/2023Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 1/17/2023 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 375.17% from -$145M to $399M, earnings per share increased from -$0.4003 to $1.1, and EBIT increased 32.17% from $286M to $378M.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 1/17/2023 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 375.17% from -$145M to $399M, earnings per share increased from -$0.4003 to $1.1, and EBIT increased 32.17% from $286M to $378M.
D
Sell
8/12/2022Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D from D- on 8/12/2022 due to a substantial increase in the efficiency index, valuation index and solvency index.
Bausch Health Companies Inc. (BHC) was upgraded to D from D- on 8/12/2022 due to a substantial increase in the efficiency index, valuation index and solvency index.
D
Sell
7/21/2022Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 7/21/2022 due to a noticeable decline in the total return index and volatility index.
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 7/21/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
5/31/2022Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D from D- on 5/31/2022 due to an increase in the valuation index.
Bausch Health Companies Inc. (BHC) was upgraded to D from D- on 5/31/2022 due to an increase in the valuation index.
D
Sell
5/13/2022Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 5/13/2022 due to a decline in the volatility index, growth index and total return index. Operating cash flow declined 362.5% from $24M to -$63M, earnings per share declined from $0.1917 to -$0.1912, and EBIT declined 32.79% from $494M to $332M.
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 5/13/2022 due to a decline in the volatility index, growth index and total return index. Operating cash flow declined 362.5% from $24M to -$63M, earnings per share declined from $0.1917 to -$0.1912, and EBIT declined 32.79% from $494M to $332M.
D
Sell
5/5/2022Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Bausch Health Companies Inc. (BHC) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
Bausch Health Companies Inc. (BHC) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
D
Sell
2/28/2022Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 2/28/2022 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 95.74% from $564M to $24M, and earnings per share declined from $0.52 to $0.1917.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 2/28/2022 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 95.74% from $564M to $24M, and earnings per share declined from $0.52 to $0.1917.
D
Sell
11/9/2021Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D- on 11/09/2021.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D- on 11/09/2021.
D
Sell
11/8/2021Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D- from D+ on 11/8/2021 due to a decline in the total return index, solvency index and volatility index.
Bausch Health Companies Inc. (BHC) was downgraded to D- from D+ on 11/8/2021 due to a decline in the total return index, solvency index and volatility index.
D
Sell
5/7/2021Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 5/7/2021 due to a large increase in the solvency index, valuation index and total return index. Debt to equity declined from 44.82 to -120.5, and the quick ratio increased from 0.44 to 0.44.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 5/7/2021 due to a large increase in the solvency index, valuation index and total return index. Debt to equity declined from 44.82 to -120.5, and the quick ratio increased from 0.44 to 0.44.
D
Sell
2/21/2020Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from C- on 2/21/2020 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.139 to -$4.3002, debt to equity increased from 9.51 to 24.41, and operating cash flow declined 54.56% from $515M to $234M.
Bausch Health Companies Inc. (BHC) was downgraded to D from C- on 2/21/2020 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.139 to -$4.3002, debt to equity increased from 9.51 to 24.41, and operating cash flow declined 54.56% from $515M to $234M.
C
Hold
1/15/2020Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to C- from D+ on 1/15/2020 due to an increase in the valuation index and volatility index.
Bausch Health Companies Inc. (BHC) was upgraded to C- from D+ on 1/15/2020 due to an increase in the valuation index and volatility index.
D
Sell
12/26/2019Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D+ from C- on 12/26/2019 due to a decline in the valuation index.
Bausch Health Companies Inc. (BHC) was downgraded to D+ from C- on 12/26/2019 due to a decline in the valuation index.
C
Hold
12/11/2019Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to C- from D+ on 12/11/2019 due to a large increase in the total return index and volatility index.
Bausch Health Companies Inc. (BHC) was upgraded to C- from D+ on 12/11/2019 due to a large increase in the total return index and volatility index.
D
Sell
11/12/2019Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 11/12/2019 due to a large increase in the growth index, efficiency index and volatility index. Earnings per share increased from -$0.4857 to -$0.139, net income increased 71.35% from -$171M to -$49M, and operating cash flow increased 51.92% from $339M to $515M.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 11/12/2019 due to a large increase in the growth index, efficiency index and volatility index. Earnings per share increased from -$0.4857 to -$0.139, net income increased 71.35% from -$171M to -$49M, and operating cash flow increased 51.92% from $339M to $515M.
D
Sell
10/2/2019Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 10/2/2019 due to a decline in the total return index.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 10/2/2019 due to a decline in the total return index.
D
Sell
9/13/2019Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 9/13/2019 due to an increase in the total return index.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 9/13/2019 due to an increase in the total return index.
D
Sell
8/28/2019Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 8/28/2019 due to a decline in the total return index.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 8/28/2019 due to a decline in the total return index.
D
Sell
8/13/2019Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 8/13/2019 due to an increase in the growth index, solvency index and efficiency index. The quick ratio increased from 0.65 to 0.73, total revenue increased 6.75% from $2.02B to $2.15B, and EBIT increased 3.5% from $286M to $296M.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 8/13/2019 due to an increase in the growth index, solvency index and efficiency index. The quick ratio increased from 0.65 to 0.73, total revenue increased 6.75% from $2.02B to $2.15B, and EBIT increased 3.5% from $286M to $296M.
D
Sell
7/16/2019Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 7/16/2019 due to a decline in the total return index and valuation index.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 7/16/2019 due to a decline in the total return index and valuation index.
D
Sell
7/1/2019Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 7/1/2019 due to an increase in the volatility index and total return index.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 7/1/2019 due to an increase in the volatility index and total return index.
D
Sell
5/29/2019Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 5/29/2019 due to a decline in the total return index and volatility index.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 5/29/2019 due to a decline in the total return index and volatility index.
D
Sell
5/9/2019Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 5/9/2019 due to a noticeable increase in the total return index and efficiency index. Net income increased 84.88% from -$344M to -$52M, and total capital increased 0.29% from $27.12B to $27.2B.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 5/9/2019 due to a noticeable increase in the total return index and efficiency index. Net income increased 84.88% from -$344M to -$52M, and total capital increased 0.29% from $27.12B to $27.2B.
D
Sell
2/15/2019Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 2/15/2019 due to a decline in the total return index.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 2/15/2019 due to a decline in the total return index.
D
Sell
1/31/2019Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 1/31/2019 due to an increase in the volatility index and total return index.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 1/31/2019 due to an increase in the volatility index and total return index.
D
Sell
12/17/2018Downgrade
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 12/17/2018 due to a decline in the total return index.
Bausch Health Companies Inc. (BHC) was downgraded to D from D+ on 12/17/2018 due to a decline in the total return index.
D
Sell
11/26/2018Upgraded
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 11/26/2018 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 214.29% from $56M to $176M, operating cash flow increased 135.14% from $222M to $522M, and earnings per share increased from -$2.49 to -$1.
Bausch Health Companies Inc. (BHC) was upgraded to D+ from D on 11/26/2018 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 214.29% from $56M to $176M, operating cash flow increased 135.14% from $222M to $522M, and earnings per share increased from -$2.49 to -$1.
D
Sell
5/11/2018Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to D from C- on 5/11/2018 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.4512 to -$7.68, net income declined 624.95% from $513M to -$2.69B, and EBIT declined 117.39% from $23M to -$4M.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to D from C- on 5/11/2018 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.4512 to -$7.68, net income declined 624.95% from $513M to -$2.69B, and EBIT declined 117.39% from $23M to -$4M.
C
Hold
3/7/2018Upgraded
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C- from D+ on 3/7/2018 due to a large increase in the total return index, efficiency index and valuation index.
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C- from D+ on 3/7/2018 due to a large increase in the total return index, efficiency index and valuation index.
D
Sell
11/13/2017Upgraded
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to D+ from D on 11/13/2017 due to a substantial increase in the valuation index and efficiency index. Net income increased 3,523.68% from -$38M to $1.3B, and total capital increased 0.22% from $32.49B to $32.56B.
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to D+ from D on 11/13/2017 due to a substantial increase in the valuation index and efficiency index. Net income increased 3,523.68% from -$38M to $1.3B, and total capital increased 0.22% from $32.49B to $32.56B.
D
Sell
4/15/2016Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to D from D+ on 4/15/2016 due to a large decline in the total return index and volatility index.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to D from D+ on 4/15/2016 due to a large decline in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to D+ from C on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 0.24% from $37.44B to $37.35B.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to D+ from C on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 0.24% from $37.44B to $37.35B.
C
Hold
7/29/2015Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C from C+ on 7/29/2015 due to a decline in the efficiency index, solvency index and valuation index. Net income declined 171.91% from $73.7M to -$53M, the quick ratio declined from 1.29 to 0.78, and debt to equity increased from 4.03 to 4.8.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C from C+ on 7/29/2015 due to a decline in the efficiency index, solvency index and valuation index. Net income declined 171.91% from $73.7M to -$53M, the quick ratio declined from 1.29 to 0.78, and debt to equity increased from 4.03 to 4.8.
C
Hold
7/23/2015Upgraded
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C+ from C on 7/23/2015 due to an increase in the total return index.
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C+ from C on 7/23/2015 due to an increase in the total return index.
C
Hold
7/6/2015Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C from C+ on 7/6/2015 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from $1.5585 to $0.21, operating cash flow declined 39.79% from $815.7M to $491.1M, and EBIT declined 10.56% from $715.3M to $639.8M.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C from C+ on 7/6/2015 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from $1.5585 to $0.21, operating cash flow declined 39.79% from $815.7M to $491.1M, and EBIT declined 10.56% from $715.3M to $639.8M.
C
Hold
4/20/2015Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C+ from B- on 4/20/2015 due to a decline in the valuation index.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C+ from B- on 4/20/2015 due to a decline in the valuation index.
B
Buy
3/31/2015Upgraded
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to B- from C+ on 3/31/2015 due to an increase in the total return index.
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to B- from C+ on 3/31/2015 due to an increase in the total return index.
C
Hold
3/16/2015Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C+ from B- on 3/16/2015 due to a decline in the valuation index.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C+ from B- on 3/16/2015 due to a decline in the valuation index.
B
Buy
2/27/2015Upgraded
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to B- from C on 2/27/2015 due to a significant increase in the total return index, growth index and volatility index. Earnings per share increased from $0.81 to $1.5585, operating cash flow increased 31.84% from $618.7M to $815.7M, and EBIT increased 23.39% from $579.7M to $715.3M.
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to B- from C on 2/27/2015 due to a significant increase in the total return index, growth index and volatility index. Earnings per share increased from $0.81 to $1.5585, operating cash flow increased 31.84% from $618.7M to $815.7M, and EBIT increased 23.39% from $579.7M to $715.3M.
C
Hold
10/28/2014Upgraded
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C from C- on 10/28/2014 due to an increase in the efficiency index, valuation index and solvency index. Net income increased 118.92% from $125.8M to $275.4M, and debt to equity declined from 3.3 to 3.18.
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C from C- on 10/28/2014 due to an increase in the efficiency index, valuation index and solvency index. Net income increased 118.92% from $125.8M to $275.4M, and debt to equity declined from 3.3 to 3.18.
C
Hold
9/12/2014Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C- from C on 9/12/2014 due to a large decline in the volatility index and valuation index.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C- from C on 9/12/2014 due to a large decline in the volatility index and valuation index.
C
Hold
8/7/2014Upgraded
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C from C- on 8/7/2014 due to a major increase in the growth index and efficiency index. EBIT increased 8.24% from $473.4M to $512.4M, total revenue increased 8.21% from $1.89B to $2.04B, and total capital increased 0.45% from $22.59B to $22.69B.
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C from C- on 8/7/2014 due to a major increase in the growth index and efficiency index. EBIT increased 8.24% from $473.4M to $512.4M, total revenue increased 8.21% from $1.89B to $2.04B, and total capital increased 0.45% from $22.59B to $22.69B.
C
Hold
5/13/2014Downgrade
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C- from C on 5/13/2014 due to a major decline in the growth index, solvency index and efficiency index. Earnings per share declined from $0.3633 to -$0.07, net income declined 118.26% from $123.77M to -$22.6M, and EBIT declined 19.49% from $588.01M to $473.4M.
Valeant Pharmaceuticals International, Inc. (VRX) was downgraded to C- from C on 5/13/2014 due to a major decline in the growth index, solvency index and efficiency index. Earnings per share declined from $0.3633 to -$0.07, net income declined 118.26% from $123.77M to -$22.6M, and EBIT declined 19.49% from $588.01M to $473.4M.
C
Hold
3/5/2014Upgraded
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C from C- on 3/5/2014 due to a substantial increase in the growth index, solvency index and volatility index. EBIT increased 59.76% from $368.05M to $588.01M, operating cash flow increased 38.75% from $201.71M to $279.87M, and total revenue increased 33.59% from $1.54B to $2.06B.
Valeant Pharmaceuticals International, Inc. (VRX) was upgraded to C from C- on 3/5/2014 due to a substantial increase in the growth index, solvency index and volatility index. EBIT increased 59.76% from $368.05M to $588.01M, operating cash flow increased 38.75% from $201.71M to $279.87M, and total revenue increased 33.59% from $1.54B to $2.06B.
NYSE
03/07/2025 3:00PM Eastern
Quotes delayed
